Northland Securities analyst Tim Chiang maintained a Hold rating on Pacira Pharmaceuticals (PCRX) today and set a price target of $75.00. The company’s shares closed last Thursday at $74.45, close to its 52-week high of $80.00.
According to TipRanks.com, Chiang is a 3-star analyst with an average return of 3.6% and a 51.6% success rate. Chiang covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Verrica Pharmaceuticals, and Kala Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pacira Pharmaceuticals with a $80.63 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $80.00 and a one-year low of $27.46. Currently, Pacira Pharmaceuticals has an average volume of 498.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
